Abattis Bioceuticals Corp (ATT) Director William Panenka Sells 25,000 Shares

Abattis Bioceuticals Corp (CNSX:ATT) Director William Panenka sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of C$0.67, for a total transaction of C$16,750.00.

William Panenka also recently made the following trade(s):

  • On Friday, January 12th, William Panenka sold 90,000 shares of Abattis Bioceuticals stock. The shares were sold at an average price of C$0.53, for a total transaction of C$47,700.00.
  • On Tuesday, December 12th, William Panenka sold 100,000 shares of Abattis Bioceuticals stock. The shares were sold at an average price of C$0.48, for a total transaction of C$48,000.00.

Shares of Abattis Bioceuticals Corp (ATT) traded up C$0.01 during midday trading on Friday, hitting C$0.61. 1,710,000 shares of the company traded hands, compared to its average volume of 2,970,000. Abattis Bioceuticals Corp has a 12-month low of C$0.05 and a 12-month high of C$0.74. The firm has a market capitalization of $136.43 and a PE ratio of -15.25.

TRADEMARK VIOLATION WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/19/abattis-bioceuticals-corp-att-director-william-panenka-sells-25000-shares.html.

Abattis Bioceuticals Company Profile

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets.

Receive News & Ratings for Abattis Bioceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abattis Bioceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply